Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children

Pediatric Infectious Disease Journal

Volumn 31, Issue 2, 2012, Pages 184-188

  Grant, Lindsay R ^a   Watt, James P ^a   Weatherholtz, Robert C ^a   Moulton, Lawrence H ^a   Reid, Raymond ^a   Santosham, Mathuram ^a   O'Brien, Katherine L ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

American Indian; Child; Gastroenteritis; Native American; Rotavirus; Vaccine

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE;

AMERICAN INDIAN; ARTICLE; CHILD; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ETHNIC DIFFERENCE; FEVER; HEALTH CARE UTILIZATION; HUMAN; IMMUNOGENICITY; INFANT; INTUSSUSCEPTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PEDIATRICS; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS; ROTAVIRUS INFECTION; SEROTYPE; VIRAL GASTROENTERITIS; VOMITING;

DOUBLE-BLIND METHOD; FEMALE; GASTROENTERITIS; HUMANS; INCIDENCE; INDIANS, NORTH AMERICAN; INFANT; MALE; PLACEBOS; REASSORTANT VIRUSES; ROTAVIRUS; ROTAVIRUS VACCINES; SEVERITY OF ILLNESS INDEX; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84858138115     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182435afe     Document Type: Article

References (18)

1. World Health Organization. The Global Burden of Disease: 2004 Update. Available at: http://www.who.int/healthinfo/global-burden-disease/2004-report- update/en/index.html. Accessed April 21, 2011.
2. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9:565-572. (Pubitemid 36529515)
3. Moulton LH, Staat MA, Santosham M, et al. The protective effectiveness of natural rotavirus infection in an American Indian population. J Infect Dis. 1998;178:1562-1566. (Pubitemid 28558123)
4. Ward RL, Bernstein DI. Protection against rotavirus disease after natural rotavirus infection. J Infect Dis. 1994;169:900-904. (Pubitemid 24102131)
5. Sack RB, Santosham M, Reid R, et al. Diarrhoeal diseases in the White Mountain Apaches: clinical studies. J Diarrhoeal Dis Res. 1995;13:12-17.
6. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Eng J Med. 2006;354:23-33. (Pubitemid 43048948)
7. Santosham M, Moulton LH, Reid R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr. 1997;131:632- 638.
8. Santosham M, Leston GW, Wolff M, et al. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population. J Infect Dis. 1991;163:483- 487.
9. Clark HF, Borian FE, Bell LM, et al. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis. 1998;158:570 -587.
10. DiStefano DJ, Kraiouchkine N, Mallette L, et al. Novel rotavirus VP7 typing assay using a one-step reverse transcriptase PCR protocol and product sequencing and utility of the assay for epidemiological studies and strain characterization, including serotype subgroup analysis. J Clin Microbiol. 2005;43:5876 -5880.
11. Laboratory-based surveillance for rotavirus-United States, July 1996-June 1997. Morb Mortal Wkly Rep. 1997;46:1092-1094.
12. LeBaron CW, Lew J, Glass RI, et al. Annual rotavirus epidemic patterns in North America: results of a 5-year retrospective survey of 88 centers in Canada, Mexico, and the United States. JAMA. 1990;264:983-988. (Pubitemid 20260909)
13. Jovanovic B, Zelenski R. Safety evaluation and confidence intervals when the number of observed events is small or zero. Ann Emerg Med. 1997;30:301-306. (Pubitemid 27371871)
14. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376:606-614.
15. Zaman K, Anh DD, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376:615- 623.
16. Goveia MG, DiNubile MJ, Dallas MJ, et al. for the REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr Infect Dis J. 2008;27:656-658.
17. Vesikari T, Itzler R, Matson DO, et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis. 2007;11:S29 -S35.
18. Jiang B, Gentsch JR, Glass RI. The role of serum antibodies in the protection against rotavirus disease: an overview. Clin Infect Dis. 2002;34:1351-1361. (Pubitemid 34507945)